Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages
October 30, 2015 12:57 PM EDTThe bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.
This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More
Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-Term
October 30, 2015 10:14 AM EDTOn the Valeant Pharma (NYSE: VRX) call, Bill Ackman said Valeant worth $180-$240 and worth $262-$350 longer term (2020).
... MoreValeant Pharma (VRX) on Watch as Ahead of Pershing Square Conference Call
October 30, 2015 8:53 AM EDTDown 7.6% currently, Valeant Pharma (NYSE: VRX) is on watch ahead of Bill Ackman's conference call, which is starting at 9:00AM ET.
During the call, Bill Ackman and other members of the Pershing Square investment team will address questions from investors... More
Valeant Pharma (VRX) Appoints Former U.S. Deputy AG Filip to Advise Ad Hoc Committee
October 30, 2015 8:46 AM EDTValeant Pharma (NYSE: VRX) announced that the ad hoc committee appointed by Valeant's board of directors has appointed former Deputy Attorney General of the United States Mark Filip of Kirkland & Ellis LLP to advise the committee in its review of allegations related to Valeant's... More
